» Authors » Yoshitsugu Obi

Yoshitsugu Obi

Explore the profile of Yoshitsugu Obi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 141
Citations 3136
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Obi Y, Xu A, Wilson J, Ephraim P, Weiner D, Scialla J, et al.
Clin J Am Soc Nephrol . 2024 Oct; 19(12):1613-1621. PMID: 39405123
No abstract available.
2.
Obi Y, Raimann J, Kalantar-Zadeh K, Murea M
Toxins (Basel) . 2024 Jul; 16(7). PMID: 39057938
Individuals afflicted with advanced kidney dysfunction who require dialysis for medical management exhibit different degrees of native kidney function, called residual kidney function (RKF), ranging from nil to appreciable levels....
3.
Siddiqui R, Obi Y, Dossabhoy N, Shafi T
Curr Hypertens Rep . 2024 Jun; 26(12):463-474. PMID: 38913113
Purpose Of Review: Chronic kidney disease and end-stage kidney disease (ESKD) are well-established risk factors for cardiovascular disease (CVD), the leading cause of mortality in the dialysis population. Conventional therapies,...
4.
Tio M, Butler J, Zhu X, Obi Y, Yen T, Kalantar-Zadeh K, et al.
J Am Soc Nephrol . 2024 May; 35(8):1076-1083. PMID: 38749547
No abstract available.
5.
Obi Y, Thomas F, Dashputre A, Goedecke P, Kovesdy C
Kidney Med . 2024 Jan; 6(1):100757. PMID: 38192434
Rationale & Objective: Patiromer is a potassium binder approved for the long-term management of hyperkalemia. Although patiromer use among patients with advanced chronic kidney disease (CKD) has been shown to...
6.
Clemmer J, Yen T, Obi Y
Physiol Rep . 2023 Nov; 11(21):e15836. PMID: 37957121
Sodium-glucose cotransporter (SGLT)-2 inhibitors have recently been approved for chronic kidney disease (CKD) based on their ability to lower proteinuria and slow CKD progression independent of diabetes status. In diabetic...
7.
Okazaki M, Obi Y, Shafi T, Rhee C, Kovesdy C, Kalantar-Zadeh K
Kidney Int Rep . 2023 Oct; 8(10):1989-2000. PMID: 37849997
Introduction: The survival benefit of residual kidney function (RKF) in patients on hemodialysis is presumably due to enhanced fluid management and solute clearance. However, data are lacking on the association...
8.
Yamada T, Puttarajappa C, Kovesdy C, Obi Y
J Am Soc Nephrol . 2023 Jun; 34(6):1121-1122. PMID: 37259197
No abstract available.
9.
Hosojima M, Kabasawa H, Kaseda R, Ishikawa-Tanaka T, Obi Y, Murayama T, et al.
Kidney360 . 2022 Dec; 3(11):1861-1870. PMID: 36514407
Background: The benefits of dietary protein restriction in CKD remain unclear, largely due to inadequate adherence in most clinical trials. We examined whether low-protein rice (LPR) previously developed to reduce...
10.
Clemmer J, Shafi T, Obi Y
Curr Hypertens Rep . 2022 Jun; 24(10):413-424. PMID: 35708820
Purpose Of Review: In this article, we summarize recent advances in understanding hypertension and cardiovascular disease in patients with end-stage kidney disease. Recent Findings: Factors such as anemia, valvular and...